All News

This year’s top content from the fall meeting of the Association of Community Cancer Centers (ACCC) highlights both treatment gains made through innovative referral, screening, and assistance initiatives and the ongoing need to improve health equity and research inclusivity.

CDC revealed nationally representative estimates of chronic fatigue; the proposed merger between Cigna and Humana has been terminated over financial terms and shareholder skepticism; ChatGPT provides inaccurate responses to medication queries.

Presenters at the American Society of Hematology Annual Meeting and Exposition agreed that novel strategies, such as CRISPR and base editing, have potential to fine-tune the latest immunotherapy advancements to increase the efficacy and durability of a range of treatments.

Chronic obstructive pulmonary disease (COPD) is associated with fatal events in the long-term prognosis of stroke, but the association between COPD and short-term death in patients with stroke is insignificant.

Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort.

These new data highlight key points about the timeline of benefits for those who quit smoking cigarettes, including respiratory and cardiovascular benefits.

Although direct-mail self-sampling significantly increased cervical cancer screening, the opt-in approach only minimally increased screening.

The decision was supported by efficacy data from 36 patients from the ongoing phase 1/2 HGB-206 trial (NCT02140554) and 2 patients in the phase 3 HGB-210 trial (NCT04293185). It was the second approval from FDA for a gene therapy for sickle cell disease.

Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.

Extended follow-up data presented at the American Society of Hematology show the advantage seen a year ago has held up for the second-generation Bruton tyrosine kinase inhibitor.

The Center on Health Equity and Access provides information on the latest news, research discoveries, and initiatives dedicated to addressing healthcare disparities and improving overall access to high-quality care.

Ana Ferrigno Guajardo, MD, discusses lingering questions following the results of a study on taxane chemotherapy interventions in patients with breast cancer during pregnancy.

Siddhartha Yadav, MD, discusses real-world data demonstrating the mass underutilization of BRCA testing in patients with breast cancer.

For the first time, researchers identified sex-based differences in genetic expression of human pulmonary microvascular endothelial cells (HPMECs).

This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.

At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.

Gabriel Hortobagyi, MD, FACP, talks about the potential for further studies in HR-positive/HER2-negative breast cancer following the results of the NATALEE trial.

Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.

Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment.

Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.

Stephanie Graff, MD, details insights from a study evaluating the perspectives and perceptions on clinical meaningfulness from patients, clinicians, and caregivers.

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

The FDA has approved a gene-editing therapy for sickle cell disease (SCD) for the first time.

This data represented the first-ever research presented at ACR on both fractures and calcium pyrophosphate deposition disease.

The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.